title: [Effects of exenatide lar in type 2 diabetes mellitus and obesity].
abstract: BACKGROUND
  GLP-1 analogs have been shown to be an effective treatment of type 2 diabetes mellitus (DM-2) and obesity.
  
  
  OBJECTIVE
  Evaluate the efficacy of exenatide LAR on weight loss, glycemic control, blood pressure (BP) and lipid profile, in DM-2 and obesity.
  
  
  METHODS
  Retrospective study of patients treated with exenatide LAR for 6 months. Demographic data (age, gender), anthropometric, fasting glucose, glycated hemoglobin (HbA1c), blood pressure and lipid profile were collected at baseline and at 6 months after treatment. We performed a logistic regression analysis to assess possible predictors of efficacy.
  
  
  RESULTS
  30 patients (17 male, mean age: 61.7 ± 9.5 years old) with DM-2 of 9.7 ± 6.2 years of evolution. HbA1c was reduced by 1.3% (95%CI 1.04-1.57; p <0.001), weight by 2.8 kg (95%CI 1.67-3.96, p <0.001) and BMI by 1.9 kg/m2 (95%CI 1,08-2,93; p <0,001). Total cholesterol decreased by 26.9 mg/dl (95%CI 9.23-38.8, p = 0.003), LDL cholesterol by 21.2 mg/dl (95% CI 7.56-34.9, p = 0.02) and triglycerides by 53.9 mg/dl (95%CI 46.4-77.1 mg/dl, p = 0.004). No statistically significant changes in blood pressure and HDL cholesterol were observed. 53.3% of patients got an HbA1c <7%, 66.6% lost weight, and 43.3% simultaneously achieved both of them. Neither of the studied variables was confirmed as a predictor of treatment response. Regarding side effects, 53.3% reported gastrointestinal discomfort (nausea) and 26.6% reported subcutaneous nodules of spontaneous resolution.
  
  
  CONCLUSIONS
  Treatment with exenatide LA, in obesity and DM-2, has shown beneficial effect on lipid weight, BMI, glycemic control and lipid profile, despite the long duration of diabetes in our patients.
authors.affiliation: Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz-idc salud. Madrid. España.. roberto.sierra@fjd.es.
authors.forename: Roberto
authors.initials: R
authors.lastname: Sierra Poyatos
authors.affiliation: Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz-idc salud. Madrid. España.. roberto.sierra@fjd.es.
authors.forename: Pilar
authors.initials: P
authors.lastname: Riobó Serván
authors.affiliation: Servicio de Endocrinología y Nutrición. Hospital Universitario Fundación Jiménez Díaz-idc salud. Madrid. España.. roberto.sierra@fjd.es.
authors.forename: Clotilde
authors.initials: C
authors.lastname: Vázquez Martínez
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D015992:Body Mass Index; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D000077270:Exenatide; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000188:drug therapy*; D010455:Peptides / Q000627:therapeutic use*; D012189:Retrospective Studies; D014688:Venoms / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D003692:Delayed-Action Preparations; D000077270:Exenatide; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D008055:Lipids; D010455:Peptides; D014688:Venoms